ClinicalTrials.gg
CompletedNCT00791492Updated Dec 17, 2012Results posted

An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy

A Phase 2/3 interventional study of Fx-1006A in Familial Amyloid Polyneuropathy and ATTR-PN, sponsored by Pfizer. Completed at 11 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-12-17.

Sponsored by Pfizer · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
86
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Amyloid Neuropathies, Familial with a site in Portugal — 4 open to participants now, 5 under way, 2 of them phase 3. Amyloid Neuropathies, Familial · Portugal.

Enrollment
9th of 10
86 · median 192
Started
2008
the only one that year
Phase 2/3
3 of 13
none open now
Registered
2nd of 13
by date
Lead sponsor
2 of 13
Pfizer

Among the 13 studies in Amyloid Neuropathies, Familial with a site in Portugal, this one is the 9th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2008, is one of 3 in phase 2/3, and was the 2nd registered.

Amyloid Neuropathies, Familial

188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.

Browse Amyloid Neuropathies, Familial studies →

Open to participants now

4 of the 13 studies in Amyloid Neuropathies, Familial with a site in Portugal are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →

Who these studies take

Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Amyloid Neuropathies, Familial with a site in Portugal, or all of them as a file.
02

Study summary

This study is designed to determine the long-term safety and tolerability of Fx-1006A as well as the effects of Fx-1006A on clinical outcomes in patients with ATTR-PN.

All patients who enroll in this extension study will receive once-daily oral 20 mg Fx-1006A for 12 months; therefore, patients randomized to placebo in Study Fx-005 will cross over to active drug (Fx-1006A 20 mg) during this study. However, patients and their families as well as clinical Investigators and their clinical site staff will remain blinded to the original Fx-005 treatment assignment. It is intended that there will be no interruption in study medication administration between the two studies. The majority of safety and clinical outcomes assessments will be identical to those evaluated in Study Fx-005. Additional assessments for this open-label extension study include 24-hour Holter monitoring and skin biopsy for IENF; patients will be required to provide written informed consent to participate in this open-label extension study prior to having these additional procedures performed.

The values obtained from procedures and evaluations conducted during the Month 18 visit of Study Fx-005 will be used as the Baseline values for this open-label extension study. The Baseline assessments of IENF and Holter monitoring may be conducted at either day of the Month 18 visit days of Study Fx-005, but prior to the first Fx-1006A dose in this open-label extension study. Clinic Visits will be conducted at Week 6 (± 2 days), and Month 3 (± 1 week), Month 6 (± 2 weeks), and Month 12 (± 2 weeks). Monthly telephone contacts (± 1 week of the scheduled date) will be made during months in which no investigative site visits are scheduled (Months 2, 4, 5, 7, 8, 9, 10, and 11) for assessment of adverse events and concomitant medications.

Neurological evaluation by NIS-LL will be performed at Months 6 and 12. The NIS-LL will be assessed by utilizing the average of two successive NIS-LL clinical assessment scores obtained at least 24 hours apart within a one week period for each study visit. A dedicated neurologist will be required to perform NIS-LL scoring across all time-points for each individual patient enrolled in the study.

Quality of life utilizing the Norfolk QOL-DN will be assessed at Months 6 and 12 (based on the total score as well as the five individual domains of the questionnaire).

QST (utilizing CASE IV), NCS, HRDB, mBMI, and echocardiography will be conducted at Months 6 and 12. Holter monitoring will be conducted at Baseline and Months 6 and 12. Biopsies for IENF will be obtained at Baseline only. Assessments of troponin I and NT-pro-BNP levels will be made at each study visit.

Blood samples for pharmacokinetic assessments (Fx-1006A concentrations as well as calculated steady-state parameters) and pharmacodynamic assessments (TTR stabilization) will be collected at Week 6 and Months 6 and 12.

Safety and tolerability will be assessed throughout the study. Vital signs, 12-lead ECG, blood and urine samples for clinical laboratory tests (serum chemistry, hematology, coagulation panel, urinalysis, and urine pregnancy testing), adverse events, and concomitant medications will be assessed at each study visit. Eye examinations (including fundal photography) will be conducted at Months 6 and 12. Abbreviated physical examinations will be conducted at Week 6, and Months 3 and 6, and a complete physical examination will be conducted at Month 12.

All patients will be contacted by telephone 30 days (± 1 week) after the last dose of study medication for assessment of adverse events and concomitant medications.

Patients who complete the Month 12 visit of this open-label study may be allowed to continue receiving Fx-1006A under a compassionate use program.

Patients who discontinue from the study at any time after enrollment (i.e., early termination) will have final safety assessments performed at the time of discontinuation. Any patient discontinuing after the Month 6 visit will have all safety and clinical outcomes assessments scheduled for the Month 12 visit performed.

03

Conditions studied

  • Familial Amyloid Polyneuropathy
  • ATTR-PN

Keywords

  • FAP
  • Familial Amyloid Polyneuropathy
  • ATTR-PN
  • transthyretin
  • TTR
  • amyloid
  • polyneuropathy
  • familial
  • hereditary
  • amyloidosis
  • FoldRx
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male and non-pregnant female patients meeting all of the following criteria are eligible for enrollment in this study:

  • Patient has completed the Month 18 visit of Study Fx-005.
  • If female, patient is , surgically sterilized, or willing to use an acceptable method of (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide) throughout the study. (A condom alone is not considered an acceptable method of birth control.) If male with a female partner of , willing to use an acceptable method of birth control for the duration of the study. For both females and males, acceptable birth control must be used for at least 3 months after the last dose of study medication.
  • Patient is, in the opinion of the investigator, willing and able to comply with the study medication regimen and all other study requirements.
  • Patient agrees not to participate in another drug or device study while participating in this open-label extension study.

Exclusion criteria

Exclusion Criteria:

Patients meeting any of the exclusion criteria will not be enrolled in the study:

  • Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs), defined as greater than 3-4 times/month (ibuprofen and nimesulide will be permitted).
  • If female, patient is pregnant or breast feeding.
  • Patient has liver function test abnormalities: (ALT) and/or aspartate transaminases (AST) >2 times (ULN) that in the medical judgment of the investigator are due to reduced liver function or active liver disease.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Fx-1006A

    Drug: Fx-1006A

Interventions

  • Fx-1006A 20mg soft gelatin capsule administered orally once daily (at the same time each day) for 12 months.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 6

    Response to treatment indicated by either improvement(decrease from baseline) or stabilization(change from baseline of 0 to less than\[\<\] 2) in NIS-LL score,based on mean of 2 scores in 1 week period.NIS-LL assessed muscle weakness,reflexes,sensation.Each item scored separately for left,right limbs.Components of muscle weakness:0(normal)-4(paralysis),higher score=more weakness;reflexes,sensation:0=normal,1=decreased,or 2=absent.Total NIS-LL score range 0-88,higher score=more impairment. For tafamidis-tafamidis group, NIS-LL baseline value of previous study FX-005(NCT00409175) used as reference.

    Time frame: Month 6

  2. Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 12

    Response to treatment indicated by either improvement(decrease from baseline) or stabilization(change from baseline of 0 to less than\[\<\] 2) in NIS-LL score,based on mean of 2 scores in 1 week period.NIS-LL assessed muscle weakness,reflexes,sensation.Each item scored separately for left,right limbs.Components of muscle weakness:0(normal)-4(paralysis),higher score=more weakness;reflexes,sensation:0=normal,1=decreased,or 2=absent.Total NIS-LL score range 0-88,higher score=more impairment. For tafamidis-tafamidis group, NIS-LL baseline value of previous study FX-005(NCT00409175) used as reference.

    Time frame: Month 12

  3. Change From Baseline in Norfolk Quality of Life- Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score at Month 6

    Norfolk QOL-DN: 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy; Item 1 to 7: related to symptoms and presence of symptoms was assessed as 1 and absence was assessed as 0. Item 8-35: related to activities of daily living and scored on a 5-point Likert scale, where 0= no problem and 4= severe problem (except item 32, where -2= much better, 0=about the same, 2=much worse). TQOL= sum of all the items, total possible score range= -2 to 138, where higher score=worse quality of life.

    Time frame: Baseline, Month 6

  4. Change From Baseline in Norfolk Quality of Life- Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score at Month 12

    Norfolk QOL-DN: 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy; Item 1 to 7: related to symptoms and presence of symptoms was assessed as 1 and absence was assessed as 0. Item 8-35: related to activities of daily living and scored on a 5-point Likert scale, where 0= no problem and 4= severe problem (except item 32, where -2= much better, 0=about the same, 2=much worse). TQOL= sum of all the items, total possible score range= -2 to 138, where higher score=worse quality of life.

    Time frame: Baseline, Month 12

Secondary outcomes

  1. Change From Baseline in Neuropathy Impairment Score - Lower Limb (NIS-LL) Score at Month 6 and 12

    NIS-LL: assessed muscle weakness, reflexes and sensation; scored separately for left and right limbs. Components of muscle weakness (hip and knee flexion, hip and knee extension, ankle dorsiflexors, ankle plantar flexors, toe extensors, toe flexors) are scored on scale 0 (normal) to 4 (paralysis), higher score=greater weakness. Components of reflexes (quadriceps femoris, triceps surae) and sensation (touch pressure, pin-prick, vibration, joint position) were scored 0 = normal, 1= decreased, or 2 = absent. Total possible NIS-LL score range 0-88, higher score=greater impairment.

    Time frame: Baseline, Month 6, 12

  2. Change From Baseline in Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Domain Scores at Month 6 and 12

    Norfolk QOL-DN: 35-item participant-rated questionnaire to assess impact of DN on QOL; Item 1-7:scored as 1=symptoms present, 0=symptoms absent. Item 8-35:scored on 5-point Likert scale: 0=no problem,4=severe problem (except item 32: -2=much better, 0=about same, 2=much worse). Norfolk QOL-DN summarized in 5 domains(score range):physical functioning/large fiber neuropathy(-2 to 58), activities of daily living(ADLs) (0 to 20), symptoms(0 to 32), small fiber neuropathy(0 to 16), autonomic neuropathy(0 to 12); higher score=greater impairment,for each. Total score=-2 to138(higher score=worse QOL).

    Time frame: Baseline, Month 6, 12

  3. Change From Baseline in Summated 7 Score for Large Nerve Fiber Function at Month 6 and 12

    Summated 7 score: composite score included five Nerve Conduction Studies (NCS) attributes (peroneal nerve distal motor latency, peroneal nerve compound muscle action potential, peroneal nerve motor conduction velocity, tibial nerve distal motor latency, and sural nerve sensory nerve action potential amplitude) along with Vibration Detection Threshold (VDT) obtained in great toes, and Heart Rate Response to Deep Breathing (HRDB) value. Score was determined through reference to normal values for age, sex and height. Total score range= -26 to 26, where higher score=worse nerve function.

    Time frame: Baseline, Month 6, 12

  4. Change From Baseline in Summated 3 Score for Small Nerve Fiber Function at Month 6 and 12

    Summated 3 Nerve Tests Small Fiber Normal Deviates Score (NTSFnds) included cooling threshold for the lower limbs, heat pain threshold for the lower limbs and HRDB. Total score range= -11.2 to 11.2, where higher score=worse nerve function.

    Time frame: Baseline, Month 6, 12

  5. Change From Baseline in Modified Body Mass Index (mBMI) at Month 6 and 12

    BMI was calculated by weight divided by height squared. mBMI was calculated by multiplying BMI by serum albumin levels to compensate for edema formation. A progressive decline in mBMI indicated worsening of disease severity.

    Time frame: Baseline, Month 6, 12

  6. Change From Baseline in Troponin I Concentration at Week 6, Month 3, 6 and 12

    Troponin I was biomarker of cardiac stress (myocardial necrosis and increased filling pressures/ left ventricular \[LV\] wall stress).

    Time frame: Baseline, Week 6, Month 3, 6, 12

  7. Change From Baseline in N-Terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) Concentration at Week 6, Month 3, 6 and 12

    NT-proBNP was biomarker of cardiac stress (myocardial necrosis and increased filling pressures/ LV wall stress).

    Time frame: Baseline, Week 6, Month 3, 6, 12

  8. Intraepidermal Nerve Fiber (IENF) Density

    IENF density was quantified in 3 millimeter (mm) immunostained skin punch biopsies containing epidermis and superficial dermis to evaluate the amount and morphological appearance of small diameter nerve fibers, both somatic and autonomic, in sensory neuropathies. It is used in diagnosing various neuropathic conditions.

    Time frame: Baseline

  9. Percentage of Participants With Stabilized Transthyretin (TTR) Tetramer

    TTR tetramer was assessed using a validated immunoturbidimetric assay. The Fraction of Initial (FOI) is the ratio of the measured TTR tetramer concentration after denaturation to the measured TTR tetramer concentration before denaturation. TTR tetramer stabilization is based on the difference between the on-treatment FOI and the baseline FOI expressed as a percentage of the baseline FOI.

    Time frame: Month 6, 12

Other outcomes

  1. Number of Participants With Treatment-emergent Serious Adverse Events (SAEs)

    An Adverse Event (AE) was any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. SAE: AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent/significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug, up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Baseline up to 30 days after last dose of study medication

  2. Number of Participants With Treatment-emergent Adverse Events Greater Than or Equal to Grade 3

    AE=any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Grade 3 (Severe) events=unacceptable or intolerable events, significantly interrupting usual daily activity, require systemic drug therapy/other treatment. Grade 4 (Life-threatening) events caused participant to be in imminent danger of death. Grade 5 (Death) events=death related to an AE. Treatment-emergent events=between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Baseline up to 30 days after last dose of study medication

  3. Number of Participants With Clinically Significant Treatment-emergent Echocardiography (ECHO) Findings

    Clinically significant ECHO findings included: LV posterior wall thickness greater than or equal to (\>=)13 mm, LV septal thickness \>= 13 mm, right ventricular thickness \>= 7 mm, ratio of peak mitral early diastolic and atrial contraction velocity (E/A ratio) \>= 2, prime septal (E/E) \>15, ejection fraction \< 50 percent (%), E deceleration time \<= 150 millisecond (ms), isovolumic relaxation time (IVRT) \<= 70 ms, any valve thickening (\> trace regurgitation in mitral, aortic, pulmonary, or tricuspid valves), abnormal respiratory variation of inferior vena cava, pericardial effusion.

    Time frame: Baseline, Day 1 up to Month 12 (anytime on-treatment)

  4. Number of Participants With Clinically Significant Treatment-emergent Electrocardiogram (ECG) Findings

    Clinically significant ECG findings included: corrected QT (QTc) \> 450 ms, QTc \>500 ms, change in QTc between 30 and 60 ms, change in QTc greater than or equal to 60 ms.

    Time frame: Baseline, Day 1 up to Month 12 (anytime on-treatment)

  5. Number of Participants With Clinically Significant Treatment-emergent Holter Monitor Findings

    Clinically significant Holter monitor findings included: atrial fibrillation/flutter, atrial tachycardia, non-sustained ventricular tachycardia (\<30 beats), sustained ventricular tachycardia (\>= 30 beats), sinus pause (RR \>2.0 second, where RR=60/heart rate), ventricular premature contractions.

    Time frame: Baseline, Day 1 up to Month 12 (anytime on-treatment)

  6. Number of Participants Who Discontinued Due to Clinical or Laboratory Adverse Events

    An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: Baseline up to Month 12

07

Results

Posted Dec 17, 2012
Limitations and caveats
Instead of intended endpoint 'heat pain and cooling threshold', results of 'summated 3 score for small nerve fiber function' were reported. Designation of outcomes as primary and secondary was based on study team input as study did not specify this.

Participant flow

Participants who completed study FX-005 (NCT00409175), were eligible for the current study FX-006 (NCT00791492).

Participant flow — Overall Study
MilestoneTafamidis-TafamidisPlacebo-Tafamidis
Started4541
Treated4441
Completed3938
Not completed63
Withdrew: Withdrawal by subject12
Withdrew: Liver transplantation51

Outcome measures

PrimaryPercentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 6

Response to treatment indicated by either improvement(decrease from baseline) or stabilization(change from baseline of 0 to less than\[\<\] 2) in NIS-LL score,based on mean of 2 scores in 1 week period.NIS-LL assessed muscle weakness,reflexes,sensation.Each item scored separately for left,right limbs.Components of muscle weakness:0(normal)-4(paralysis),higher score=more weakness;reflexes,sensation:0=normal,1=decreased,or 2=absent.Total NIS-LL score range 0-88,higher score=more impairment. For tafamidis-tafamidis group, NIS-LL baseline value of previous study FX-005(NCT00409175) used as reference.

Time frame:
Month 6
Reported as:
Number · percentage of participants
Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 6
percentage of participantsTafamidis-TafamidisPlacebo-Tafamidis
Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 662.2 (44.8 to 77.5)68.8 (50.0 to 83.9)
PrimaryPercentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 12

Response to treatment indicated by either improvement(decrease from baseline) or stabilization(change from baseline of 0 to less than\[\<\] 2) in NIS-LL score,based on mean of 2 scores in 1 week period.NIS-LL assessed muscle weakness,reflexes,sensation.Each item scored separately for left,right limbs.Components of muscle weakness:0(normal)-4(paralysis),higher score=more weakness;reflexes,sensation:0=normal,1=decreased,or 2=absent.Total NIS-LL score range 0-88,higher score=more impairment. For tafamidis-tafamidis group, NIS-LL baseline value of previous study FX-005(NCT00409175) used as reference.

Time frame:
Month 12
Reported as:
Number · percentage of participants
Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 12
percentage of participantsTafamidis-TafamidisPlacebo-Tafamidis
Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 1254.5 (36.4 to 71.9)60.0 (40.6 to 77.3)
PrimaryChange From Baseline in Norfolk Quality of Life- Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score at Month 6

Norfolk QOL-DN: 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy; Item 1 to 7: related to symptoms and presence of symptoms was assessed as 1 and absence was assessed as 0. Item 8-35: related to activities of daily living and scored on a 5-point Likert scale, where 0= no problem and 4= severe problem (except item 32, where -2= much better, 0=about the same, 2=much worse). TQOL= sum of all the items, total possible score range= -2 to 138, where higher score=worse quality of life.

Time frame:
Baseline, Month 6
Reported as:
Mean · units on a scale
Change From Baseline in Norfolk Quality of Life- Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score at Month 6
units on a scaleTafamidis-TafamidisPlacebo-Tafamidis
Baseline21.05 ± 21.8838.09 ± 31.89
Change at Month 60.03 ± 8.83-4.88 ± 15.29
PrimaryChange From Baseline in Norfolk Quality of Life- Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score at Month 12

Norfolk QOL-DN: 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy; Item 1 to 7: related to symptoms and presence of symptoms was assessed as 1 and absence was assessed as 0. Item 8-35: related to activities of daily living and scored on a 5-point Likert scale, where 0= no problem and 4= severe problem (except item 32, where -2= much better, 0=about the same, 2=much worse). TQOL= sum of all the items, total possible score range= -2 to 138, where higher score=worse quality of life.

Time frame:
Baseline, Month 12
Reported as:
Mean · units on a scale
Change From Baseline in Norfolk Quality of Life- Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score at Month 12
units on a scaleTafamidis-TafamidisPlacebo-Tafamidis
Change From Baseline in Norfolk Quality of Life- Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score at Month 122.25 ± 8.91-2.33 ± 15.66
SecondaryChange From Baseline in Neuropathy Impairment Score - Lower Limb (NIS-LL) Score at Month 6 and 12

NIS-LL: assessed muscle weakness, reflexes and sensation; scored separately for left and right limbs. Components of muscle weakness (hip and knee flexion, hip and knee extension, ankle dorsiflexors, ankle plantar flexors, toe extensors, toe flexors) are scored on scale 0 (normal) to 4 (paralysis), higher score=greater weakness. Components of reflexes (quadriceps femoris, triceps surae) and sensation (touch pressure, pin-prick, vibration, joint position) were scored 0 = normal, 1= decreased, or 2 = absent. Total possible NIS-LL score range 0-88, higher score=greater impairment.

Time frame:
Baseline, Month 6, 12
Reported as:
Mean · units on a scale
Change From Baseline in Neuropathy Impairment Score - Lower Limb (NIS-LL) Score at Month 6 and 12
units on a scaleTafamidis-TafamidisPlacebo-Tafamidis
Baseline (n=38,33)8.38 ± 13.2317.50 ± 20.82
Change at Month 6 (n=37,32)0.93 ± 3.651.89 ± 4.55
Change at Month 12 (n=33,30)1.36 ± 4.771.60 ± 8.20
SecondaryChange From Baseline in Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Domain Scores at Month 6 and 12

Norfolk QOL-DN: 35-item participant-rated questionnaire to assess impact of DN on QOL; Item 1-7:scored as 1=symptoms present, 0=symptoms absent. Item 8-35:scored on 5-point Likert scale: 0=no problem,4=severe problem (except item 32: -2=much better, 0=about same, 2=much worse). Norfolk QOL-DN summarized in 5 domains(score range):physical functioning/large fiber neuropathy(-2 to 58), activities of daily living(ADLs) (0 to 20), symptoms(0 to 32), small fiber neuropathy(0 to 16), autonomic neuropathy(0 to 12); higher score=greater impairment,for each. Total score=-2 to138(higher score=worse QOL).

Time frame:
Baseline, Month 6, 12
Reported as:
Mean · units on a scale
Change From Baseline in Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Domain Scores at Month 6 and 12
units on a scaleTafamidis-TafamidisPlacebo-Tafamidis
Baseline: physical functioning (n=38,33)9.45 ± 11.4319.88 ± 17.44
Baseline: ADLs (n=38,33)2.21 ± 4.383.48 ± 5.13
Baseline: symptoms (n=38,33)5.34 ± 4.437.48 ± 5.48
Baseline: small fiber neuropathy (n=38,33)2.50 ± 3.854.42 ± 4.23
Baseline: autonomic neuropathy (n=38,33)1.55 ± 2.372.82 ± 3.12
Change at Month 6: physical functioning (n=37,32)0.14 ± 4.08-3.00 ± 8.08
Change at Month 6: ADLs (n=37,32)-0.30 ± 1.45-0.59 ± 3.02
Change at Month 6: symptoms (n=34,32)0.00 ± 3.18-0.75 ± 4.27
Change at Month 6: small fiber neuropathy(n=37,32)-0.14 ± 2.64-0.09 ± 2.32
Change at Month 6: autonomic neuropathy (n=37,32)0.19 ± 1.33-0.44 ± 2.00
Change at Month 12: physical functioning(n=32,30)1.84 ± 6.00-0.83 ± 9.62
Change at Month 12: ADLs (n=32,30)0.13 ± 1.01-0.50 ± 3.35
Change at Month 12: symptoms (n=32,30)-0.66 ± 2.54-1.10 ± 3.32
Change at Month 12:small fiber neuropathy(n=32,30)0.41 ± 2.870.40 ± 2.61
Change at Month 12: autonomic neuropathy (n=32,30)0.53 ± 1.46-0.30 ± 1.66
SecondaryChange From Baseline in Summated 7 Score for Large Nerve Fiber Function at Month 6 and 12

Summated 7 score: composite score included five Nerve Conduction Studies (NCS) attributes (peroneal nerve distal motor latency, peroneal nerve compound muscle action potential, peroneal nerve motor conduction velocity, tibial nerve distal motor latency, and sural nerve sensory nerve action potential amplitude) along with Vibration Detection Threshold (VDT) obtained in great toes, and Heart Rate Response to Deep Breathing (HRDB) value. Score was determined through reference to normal values for age, sex and height. Total score range= -26 to 26, where higher score=worse nerve function.

Time frame:
Baseline, Month 6, 12
Reported as:
Mean · units on a scale
Change From Baseline in Summated 7 Score for Large Nerve Fiber Function at Month 6 and 12
units on a scaleTafamidis-TafamidisPlacebo-Tafamidis
Baseline (n=38,33)6.68 ± 8.5110.06 ± 10.68
Change at Month 6 (n=37,32)-0.01 ± 2.991.38 ± 3.58
Change at Month 12 (n=33,30)0.64 ± 3.231.48 ± 4.02
SecondaryChange From Baseline in Summated 3 Score for Small Nerve Fiber Function at Month 6 and 12

Summated 3 Nerve Tests Small Fiber Normal Deviates Score (NTSFnds) included cooling threshold for the lower limbs, heat pain threshold for the lower limbs and HRDB. Total score range= -11.2 to 11.2, where higher score=worse nerve function.

Time frame:
Baseline, Month 6, 12
Reported as:
Mean · units on a scale
Change From Baseline in Summated 3 Score for Small Nerve Fiber Function at Month 6 and 12
units on a scaleTafamidis-TafamidisPlacebo-Tafamidis
Baseline (n=38,33)4.78 ± 4.337.08 ± 4.39
Change at Month 6 (n=36,32)0.43 ± 1.510.38 ± 1.08
Change at Month 12 (n=32,30)0.59 ± 1.280.50 ± 1.48
SecondaryChange From Baseline in Modified Body Mass Index (mBMI) at Month 6 and 12

BMI was calculated by weight divided by height squared. mBMI was calculated by multiplying BMI by serum albumin levels to compensate for edema formation. A progressive decline in mBMI indicated worsening of disease severity.

Time frame:
Baseline, Month 6, 12
Reported as:
Mean · (kilogram/square meter)*(gram/liter)
Change From Baseline in Modified Body Mass Index (mBMI) at Month 6 and 12
(kilogram/square meter)*(gram/liter)Tafamidis-TafamidisPlacebo-Tafamidis
Baseline (n=38,33)23.94 ± 2.9722.71 ± 5.15
Change at Month 6 (n=37,32)-0.13 ± 0.810.42 ± 1.14
Change at Month 12 (n=33,30)-0.12 ± 1.160.73 ± 1.45
SecondaryChange From Baseline in Troponin I Concentration at Week 6, Month 3, 6 and 12

Troponin I was biomarker of cardiac stress (myocardial necrosis and increased filling pressures/ left ventricular \[LV\] wall stress).

Time frame:
Baseline, Week 6, Month 3, 6, 12
Reported as:
Median · nanogram/milliliter (ng/mL)
Change From Baseline in Troponin I Concentration at Week 6, Month 3, 6 and 12
nanogram/milliliter (ng/mL)Tafamidis-TafamidisPlacebo-Tafamidis
Baseline (n=29,30)0.2 (0.2 to 0.5)0.2 (0.2 to 0.2)
Change at Week 6 (n=28,29)0.0 (0.0 to 0.1)0.0 (0.0 to 0.0)
Change at Month 3 (n=29,30)0.0 (-0.1 to 0.3)0.0 (0.0 to 0.7)
Change at Month 6 (n=29,30)0.0 (0.0 to 0.6)0.0 (0.0 to 0.1)
Change at Month 12 (n=26,28)0.0 (-0.3 to 0.4)0.0 (0.0 to 0.0)
SecondaryChange From Baseline in N-Terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) Concentration at Week 6, Month 3, 6 and 12

NT-proBNP was biomarker of cardiac stress (myocardial necrosis and increased filling pressures/ LV wall stress).

Time frame:
Baseline, Week 6, Month 3, 6, 12
Reported as:
Median · picogram/milliliter (pg/mL)
Change From Baseline in N-Terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) Concentration at Week 6, Month 3, 6 and 12
picogram/milliliter (pg/mL)Tafamidis-TafamidisPlacebo-Tafamidis
Baseline (n=33,34)41.0 (19.0 to 2879.0)75.0 (20.0 to 1127.0)
Change at Week 6 (n=33,33)6.0 (-650.0 to 525.0)-1.0 (-292.0 to 97.0)
Change at Month 3 (n=33,34)11.0 (-52.0 to 1355.0)1.0 (-514.0 to 229.0)
Change at Month 6 (n=33,33)9.0 (-210.0 to 3878.0)0.0 (-473.0 to 170.0)
Change at Month 12 (n=30,29)15.0 (-104.0 to 3840.0)-6.0 (-342.0 to 410.0)
SecondaryIntraepidermal Nerve Fiber (IENF) Density

IENF density was quantified in 3 millimeter (mm) immunostained skin punch biopsies containing epidermis and superficial dermis to evaluate the amount and morphological appearance of small diameter nerve fibers, both somatic and autonomic, in sensory neuropathies. It is used in diagnosing various neuropathic conditions.

Time frame:
Baseline
Reported as:
Mean · fibers/mm
Intraepidermal Nerve Fiber (IENF) Density
fibers/mmTafamidis-TafamidisPlacebo-Tafamidis
Left distal leg8.2 ± 9.88.0 ± 9.2
Left proximal thigh16.1 ± 12.615.3 ± 11.9
SecondaryPercentage of Participants With Stabilized Transthyretin (TTR) Tetramer

TTR tetramer was assessed using a validated immunoturbidimetric assay. The Fraction of Initial (FOI) is the ratio of the measured TTR tetramer concentration after denaturation to the measured TTR tetramer concentration before denaturation. TTR tetramer stabilization is based on the difference between the on-treatment FOI and the baseline FOI expressed as a percentage of the baseline FOI.

Time frame:
Month 6, 12
Reported as:
Number · percentage of participants
Percentage of Participants With Stabilized Transthyretin (TTR) Tetramer
percentage of participantsTafamidis-TafamidisPlacebo-Tafamidis
Month 694 (81 to 99)97 (83 to 99)
Month 1294 (80 to 99)93 (77 to 99)
Other pre-specifiedNumber of Participants With Treatment-emergent Serious Adverse Events (SAEs)

An Adverse Event (AE) was any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. SAE: AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent/significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug, up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Baseline up to 30 days after last dose of study medication
Reported as:
Number · participants
Number of Participants With Treatment-emergent Serious Adverse Events (SAEs)
participantsTafamidis-TafamidisPlacebo-Tafamidis
Number of Participants With Treatment-emergent Serious Adverse Events (SAEs)54
Other pre-specifiedNumber of Participants With Treatment-emergent Adverse Events Greater Than or Equal to Grade 3

AE=any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Grade 3 (Severe) events=unacceptable or intolerable events, significantly interrupting usual daily activity, require systemic drug therapy/other treatment. Grade 4 (Life-threatening) events caused participant to be in imminent danger of death. Grade 5 (Death) events=death related to an AE. Treatment-emergent events=between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Baseline up to 30 days after last dose of study medication
Reported as:
Number · participants
Number of Participants With Treatment-emergent Adverse Events Greater Than or Equal to Grade 3
participantsTafamidis-TafamidisPlacebo-Tafamidis
Number of Participants With Treatment-emergent Adverse Events Greater Than or Equal to Grade 364
Other pre-specifiedNumber of Participants With Clinically Significant Treatment-emergent Echocardiography (ECHO) Findings

Clinically significant ECHO findings included: LV posterior wall thickness greater than or equal to (\>=)13 mm, LV septal thickness \>= 13 mm, right ventricular thickness \>= 7 mm, ratio of peak mitral early diastolic and atrial contraction velocity (E/A ratio) \>= 2, prime septal (E/E) \>15, ejection fraction \< 50 percent (%), E deceleration time \<= 150 millisecond (ms), isovolumic relaxation time (IVRT) \<= 70 ms, any valve thickening (\> trace regurgitation in mitral, aortic, pulmonary, or tricuspid valves), abnormal respiratory variation of inferior vena cava, pericardial effusion.

Time frame:
Baseline, Day 1 up to Month 12 (anytime on-treatment)
Reported as:
Number · participants
Number of Participants With Clinically Significant Treatment-emergent Echocardiography (ECHO) Findings
participantsTafamidis-TafamidisPlacebo-Tafamidis
Baseline (n=38,34)2318
Anytime on-treatment (n=21,23)1613
Other pre-specifiedNumber of Participants With Clinically Significant Treatment-emergent Electrocardiogram (ECG) Findings

Clinically significant ECG findings included: corrected QT (QTc) \> 450 ms, QTc \>500 ms, change in QTc between 30 and 60 ms, change in QTc greater than or equal to 60 ms.

Time frame:
Baseline, Day 1 up to Month 12 (anytime on-treatment)
Reported as:
Number · participants
Number of Participants With Clinically Significant Treatment-emergent Electrocardiogram (ECG) Findings
participantsTafamidis-TafamidisPlacebo-Tafamidis
Baseline (n=44,41)1617
Anytime on-treatment (n=28,24)66
Other pre-specifiedNumber of Participants With Clinically Significant Treatment-emergent Holter Monitor Findings

Clinically significant Holter monitor findings included: atrial fibrillation/flutter, atrial tachycardia, non-sustained ventricular tachycardia (\<30 beats), sustained ventricular tachycardia (\>= 30 beats), sinus pause (RR \>2.0 second, where RR=60/heart rate), ventricular premature contractions.

Time frame:
Baseline, Day 1 up to Month 12 (anytime on-treatment)
Reported as:
Number · participants
Number of Participants With Clinically Significant Treatment-emergent Holter Monitor Findings
participantsTafamidis-TafamidisPlacebo-Tafamidis
Baseline (n=44,41)2021
Anytime on-treatment (n=24,20)87
Other pre-specifiedNumber of Participants Who Discontinued Due to Clinical or Laboratory Adverse Events

An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame:
Baseline up to Month 12
Reported as:
Number · participants
Number of Participants Who Discontinued Due to Clinical or Laboratory Adverse Events
participantsTafamidis-TafamidisPlacebo-Tafamidis
Number of Participants Who Discontinued Due to Clinical or Laboratory Adverse Events00

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tafamidis-Tafamidis—5/44 (11.4%)24/44 (54.5%)
Placebo-Tafamidis—4/41 (9.8%)24/41 (58.5%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventTafamidis-TafamidisPlacebo-Tafamidis
VomitingGastrointestinal disorders2/441/41
AnaemiaBlood and lymphatic system disorders0/441/41
NauseaGastrointestinal disorders1/441/41
InfectionInfections and infestations0/441/41
MeningitisInfections and infestations0/441/41
OsteomyelitisInfections and infestations0/441/41
Urinary tract infectionInfections and infestations0/441/41
DehydrationMetabolism and nutrition disorders0/441/41
HypersensitivityImmune system disorders1/440/41
Catheter sepsisInfections and infestations1/440/41
Most frequent other events
Showing 10 of 11
Most frequent other events
EventTafamidis-TafamidisPlacebo-Tafamidis
InfluenzaInfections and infestations3/447/41
Urinary tract infectionInfections and infestations5/446/41
HeadacheNervous system disorders2/446/41
AnxietyPsychiatric disorders1/445/41
NasopharyngitisInfections and infestations5/443/41
VomitingGastrointestinal disorders2/444/41
Thermal burnInjury, poisoning and procedural complications4/444/41
DiarrhoeaGastrointestinal disorders4/443/41
Punctate keratitisEye disorders3/443/41
Dry eyeEye disorders2/443/41

Baseline characteristics

Age Continuous
Age Continuous(years)Tafamidis-TafamidisPlacebo-TafamidisTotal
Mean41.3 ± 13.439.6 ± 13.240.4 ± 13.3
Sex: Female, Male
Sex: Female, Male(Participants)Tafamidis-TafamidisPlacebo-TafamidisTotal
Female242347
Male201838
08

Study locations

11 sites
  • FLENI Departamento de Hepatología y Transplante de Organos
    Buenos Aires, Argentina
  • FLENI-Hepatology and Organ Transplant Dept.
    Ciudad de Buenos Aires, C1428AQK, Argentina
  • Hospital Universitario Clementino Fraga Filho
    Rio de Janeiro, Brazil
  • Service de Neurologie, CHU Henri Mondor
    Paris, France
  • Universitatsklinikum Munster, Transplant Hepatology
    Munster, Germany
  • Serviço de Neurologia-Hospital de Santa Maria
    Lisboa, 1649-035, Portugal
  • Servicio de Neurologica Piso 7, Hospital de Santa Maria
    Lisbon, Portugal
  • Unidade Clinica de Paramiloidose-Hospital Santo Antonio
    Porto, 4099-001, Portugal
  • Unidade Clinica de Paramiloidose, Hospital Geral de Santo Antonio, Largo Prof Abdel Salazar
    Porto, Portugal
  • Umea University Hospital
    Umea, SE-901 85, Sweden
  • FAP-Teamet Familjar Amyloids, Norrlands universitetssjukhus
    Umea, Sweden
09

References and documents

Publications

  • Merlini G, Coelho T, Waddington Cruz M, Li H, Stewart M, Ebede B. Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyretin Amyloidosis with Polyneuropathy: Clinical Trial Results up to 8.5 Years. Neurol Ther. 2020 Jun;9(1):105-115. doi: 10.1007/s40120-020-00180-w. Epub 2020 Feb 27. PubMed 32107748 ↗
  • Huber P, Flynn A, Sultan MB, Li H, Rill D, Ebede B, Gundapaneni B, Schwartz JH. A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy. Amyloid. 2019 Dec;26(4):203-209. doi: 10.1080/13506129.2019.1643714. Epub 2019 Jul 27. PubMed 31353964 ↗
  • Amass L, Li H, Gundapaneni BK, Schwartz JH, Keohane DJ. Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy. Orphanet J Rare Dis. 2018 Dec 17;13(1):225. doi: 10.1186/s13023-018-0947-7. PubMed 30558645 ↗
  • Waddington Cruz M, Amass L, Keohane D, Schwartz J, Li H, Gundapaneni B. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid. 2016 Sep;23(3):178-183. doi: 10.1080/13506129.2016.1207163. Epub 2016 Aug 5. PubMed 27494299 ↗
  • Coelho T, Maia LF, da Silva AM, Cruz MW, Plante-Bordeneuve V, Suhr OB, Conceicao I, Schmidt HH, Trigo P, Kelly JW, Labaudiniere R, Chan J, Packman J, Grogan DR. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013 Nov;260(11):2802-14. doi: 10.1007/s00415-013-7051-7. Epub 2013 Aug 22. PubMed 23974642 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of Aug 2008 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2012, 4 years 4 months after primary completion. A results delay was requested in Feb 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2008
First posted
Nov 14, 2008
Start
Jul 2008
Primary completionActual
Aug 2008
CompletionActual
Oct 2010
Results delay requested
Feb 8, 2011
Results first posted
Dec 17, 2012
Last update
Dec 17, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00791492
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 14, 2008
Start date
Jul 2008
Primary completion
Aug 2008
Completion
Oct 2010
Results posted
Dec 17, 2012
Last update
Dec 17, 2012

Study contacts

Jeff Packman
study director · FoldRx Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tafamidis

Start the discussion